Chemistry:SRX246

From HandWiki
Short description: Chemical compound
SRX246
Clinical data
ATC code
  • None
Identifiers
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC42H49N5O5
Molar mass703.884 g·mol−1
3D model (JSmol)

SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders.[1][2][3] It is an azetidinone derivative, and was developed from LY-307174 as a lead compound.[4] A phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder is ongoing.[5] It is also being studied for the treatment of post-traumatic stress disorder.[6]

See also

References

  1. ↑ "Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist". Journal of Pharmaceutical Sciences 102 (6): 2033–2043. June 2013. doi:10.1002/jps.23495. PMID 23471831. 
  2. ↑ "Vasopressin antagonists as anxiolytics and antidepressants: recent developments". Recent Patents on CNS Drug Discovery 3 (2): 77–93. June 2008. doi:10.2174/157488908784534586. PMID 18537767. 
  3. ↑ The Routledge International Handbook of Biosocial Criminology. Routledge. 5 December 2014. pp. 241–. ISBN 978-1-317-93674-9. https://books.google.com/books?id=Bmy2BQAAQBAJ&pg=PA241. 
  4. ↑ "Azetidinones as vasopressin V1a antagonists". Bioorganic & Medicinal Chemistry 15 (5): 2054–80. March 2007. doi:10.1016/j.bmc.2006.12.031. PMID 17234419. 
  5. ↑ Clinical trial number NCT02055638 for "Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)" at ClinicalTrials.gov
  6. ↑ "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews. Drug Discovery 12 (9): 667–87. September 2013. doi:10.1038/nrd4075. PMID 23989795.